— Publications

2018 Full-Year Results (unaudited)


Download
All financial reports


— Media releases


January 31, 2019

Valneva Reports Positive Initial Booster Data and Final Phase 1 Data for its Lyme Disease Vaccine Candidate

Read more


— Financial calendar


Upcoming events
2018 Consolidated and Statutory Financial Statements (audited)
March 21, 2019



All dates




— Lyme Disease

Download brochure









    

— Our responsibility

Committed to people, protecting lives and the environment


Learn more

play video
“We have the only
clinical-stage vaccine program
against Lyme disease 
worldwide.”

Valneva's CEO Thomas Lingelbach
comments on Group Strategy

Subscribe to our Newsletter

mail-icon-lightblue.png


Contact Investor Relations

speech-balloon-icon-white.png

Please update your browser...